FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1939864032> ?p ?o ?g. }

• W1939864032 endingPage "1808" @default.
• W1939864032 startingPage "1808" @default.
• W1939864032 abstract "<h3>Importance</h3> Advantages of using efavirenz as part of treatment for children infected with human immunodeficiency virus (HIV) include once-daily dosing, simplification of co-treatment for tuberculosis, preservation of ritonavir-boosted lopinavir for second-line treatment, and harmonization of adult and pediatric treatment regimens. However, there have been concerns about possible reduced viral efficacy of efavirenz in children exposed to nevirapine for prevention of mother-to-child transmission. <h3>Objective</h3> To evaluate whether nevirapine-exposed children achieving initial viral suppression with ritonavir-boosted lopinavir–based therapy can transition to efavirenz-based therapy without risk of viral failure. <h3>Design, Setting, and Participants</h3> Randomized, open-label noninferiority trial conducted at Rahima Moosa Mother and Child Hospital, Johannesburg, South Africa, from June 2010 to December 2013, enrolling 300 HIV-infected children exposed to nevirapine for prevention of mother-to-child transmission who were aged 3 years or older and had plasma HIV RNA of less than 50 copies/mL during ritonavir-boosted lopinavir–based therapy; 298 were randomized and 292 (98%) were followed up to 48 weeks after randomization. <h3>Interventions</h3> Participants were randomly assigned to switch to efavirenz-based therapy (n = 150) or continue ritonavir-boosted lopinavir–based therapy (n = 148). <h3>Main Outcomes and Measures</h3> Risk difference between groups in (1) viral rebound (ie, ≥1 HIV RNA measurement of >50 copies/mL) and (2) viral failure (ie, confirmed HIV RNA >1000 copies/mL) with a noninferiority bound of −0.10. Immunologic and clinical responses were secondary end points. <h3>Results</h3> The Kaplan-Meier probability of viral rebound by 48 weeks was 0.176 (n = 26) in the efavirenz group and 0.284 (n = 42) in the ritonavir-boosted lopinavir group. Probabilities of viral failure were 0.027 (n = 4) in the efavirenz group and 0.020 (n = 3) in the ritonavir-boosted lopinavir group. The risk difference for viral rebound was 0.107 (1-sided 95% CI, 0.028 to ∞) and for viral failure was −0.007 (1-sided 95% CI, −0.036 to ∞). We rejected the null hypothesis that efavirenz is inferior to ritonavir-boosted lopinavir (<i>P</i> < .001) for both end points. By 48 weeks, CD4 cell percentage was 2.88% (95% CI, 1.26%-4.49%) higher in the efavirenz group than in the ritonavir-boosted lopinavir group. <h3>Conclusions and Relevance</h3> Among HIV-infected children exposed to nevirapine for prevention of mother-to-child transmission and with initial viral suppression with ritonavir-boosted lopinavir–based therapy, switching to efavirenz-based therapy compared with continuing ritonavir-boosted lopinavir–based therapy did not result in significantly higher rates of viral rebound or viral failure. This therapeutic approach may offer advantages in children such as these. <h3>Trial Registration</h3> clinicaltrials.gov Identifier:NCT01146873" @default.
• W1939864032 created "2016-06-24" @default.
• W1939864032 creator A5014482412 @default.
• W1939864032 creator A5025729929 @default.
• W1939864032 creator A5031443264 @default.
• W1939864032 creator A5038444938 @default.
• W1939864032 creator A5038561962 @default.
• W1939864032 creator A5043806838 @default.
• W1939864032 creator A5058881734 @default.
• W1939864032 creator A5065078265 @default.
• W1939864032 creator A5076365121 @default.
• W1939864032 creator A5085852744 @default.
• W1939864032 date "2015-11-03" @default.
• W1939864032 modified "2023-10-14" @default.
• W1939864032 title "Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa" @default.
• W1939864032 cites W178626500 @default.
• W1939864032 cites W1974851046 @default.
• W1939864032 cites W1975735670 @default.
• W1939864032 cites W1978268794 @default.
• W1939864032 cites W1991186486 @default.
• W1939864032 cites W2000416073 @default.
• W1939864032 cites W2001544917 @default.
• W1939864032 cites W2002432974 @default.
• W1939864032 cites W2025802167 @default.
• W1939864032 cites W2039734639 @default.
• W1939864032 cites W2055733693 @default.
• W1939864032 cites W2055889918 @default.
• W1939864032 cites W2057764123 @default.
• W1939864032 cites W2058207881 @default.
• W1939864032 cites W2062407430 @default.
• W1939864032 cites W2067563640 @default.
• W1939864032 cites W2094340292 @default.
• W1939864032 cites W2107518873 @default.
• W1939864032 cites W2121737909 @default.
• W1939864032 cites W2123179942 @default.
• W1939864032 cites W2124330138 @default.
• W1939864032 cites W2132011135 @default.
• W1939864032 cites W2133652309 @default.
• W1939864032 cites W2134746895 @default.
• W1939864032 cites W2149545619 @default.
• W1939864032 cites W2157593793 @default.
• W1939864032 cites W2164399329 @default.
• W1939864032 cites W2167796366 @default.
• W1939864032 cites W2169221951 @default.
• W1939864032 cites W2184002906 @default.
• W1939864032 cites W3014842305 @default.
• W1939864032 doi "https://doi.org/10.1001/jama.2015.13631" @default.
• W1939864032 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4655876" @default.
• W1939864032 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26529159" @default.
• W1939864032 hasPublicationYear "2015" @default.
• W1939864032 type Work @default.
• W1939864032 sameAs 1939864032 @default.
• W1939864032 citedByCount "40" @default.
• W1939864032 countsByYear W19398640322015 @default.
• W1939864032 countsByYear W19398640322016 @default.
• W1939864032 countsByYear W19398640322017 @default.
• W1939864032 countsByYear W19398640322018 @default.
• W1939864032 countsByYear W19398640322019 @default.
• W1939864032 countsByYear W19398640322020 @default.
• W1939864032 countsByYear W19398640322021 @default.
• W1939864032 countsByYear W19398640322022 @default.
• W1939864032 crossrefType "journal-article" @default.
• W1939864032 hasAuthorship W1939864032A5014482412 @default.
• W1939864032 hasAuthorship W1939864032A5025729929 @default.
• W1939864032 hasAuthorship W1939864032A5031443264 @default.
• W1939864032 hasAuthorship W1939864032A5038444938 @default.
• W1939864032 hasAuthorship W1939864032A5038561962 @default.
• W1939864032 hasAuthorship W1939864032A5043806838 @default.
• W1939864032 hasAuthorship W1939864032A5058881734 @default.
• W1939864032 hasAuthorship W1939864032A5065078265 @default.
• W1939864032 hasAuthorship W1939864032A5076365121 @default.
• W1939864032 hasAuthorship W1939864032A5085852744 @default.
• W1939864032 hasBestOaLocation W19398640321 @default.
• W1939864032 hasConcept C126322002 @default.
• W1939864032 hasConcept C142462285 @default.
• W1939864032 hasConcept C159047783 @default.
• W1939864032 hasConcept C187212893 @default.
• W1939864032 hasConcept C2777182164 @default.
• W1939864032 hasConcept C2779130552 @default.
• W1939864032 hasConcept C2779298103 @default.
• W1939864032 hasConcept C2781392899 @default.
• W1939864032 hasConcept C2781432083 @default.
• W1939864032 hasConcept C2993143319 @default.
• W1939864032 hasConcept C3013748606 @default.
• W1939864032 hasConcept C71924100 @default.
• W1939864032 hasConceptScore W1939864032C126322002 @default.
• W1939864032 hasConceptScore W1939864032C142462285 @default.
• W1939864032 hasConceptScore W1939864032C159047783 @default.
• W1939864032 hasConceptScore W1939864032C187212893 @default.
• W1939864032 hasConceptScore W1939864032C2777182164 @default.
• W1939864032 hasConceptScore W1939864032C2779130552 @default.
• W1939864032 hasConceptScore W1939864032C2779298103 @default.
• W1939864032 hasConceptScore W1939864032C2781392899 @default.
• W1939864032 hasConceptScore W1939864032C2781432083 @default.
• W1939864032 hasConceptScore W1939864032C2993143319 @default.
• W1939864032 hasConceptScore W1939864032C3013748606 @default.
• W1939864032 hasConceptScore W1939864032C71924100 @default.
• W1939864032 hasIssue "17" @default.

• next